Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Venous Thrombosis 1Venous Thromboembolism 1Thromboembolism 1Pulmonary Embolism 1Pancreatic Neoplasms 1Kidney Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Sunitinib 14aldesleukin 10Bevacizumab 8pembrolizumab 7Nivolumab 7pazopanib 5Axitinib 5atezolizumab 4Interferon-alpha 4sintilimab 3durvalumab 3Sorafenib 3Everolimus 3Cyclophosphamide 3Chemotherapy, Adjuvant 3toripalimab 2sargramostim 2olaparib 2lenvatinib 2fludarabine phosphate 2camrelizumab 2avelumab 2Neoadjuvant Therapy 2Laparoscopy 2Ipilimumab 2Interferon alpha-2 2Immunohistochemistry 2Immune Checkpoint Inhibitors 2Gene Expression Profiling 2Fluorouracil 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Carcinoma, Renal Cell × Tinzaparin × Clear all
NCT00293501 2013-11-06

Tinzaparin in Treating Patients With Metastatic Kidney Cancer That Cannot Be Removed By Surgery

National Cancer Institute (NCI)

Phase 1/2 Unknown
35 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡